New ways to successfully target tumor vasculature in ovarian cancer.

Abstract

PURPOSE OF REVIEW:

The aim of this article was to review the recent literature on potential therapeutic strategies for overcoming resistance to antivascular endothelial growth factor drugs in ovarian cancer.

RECENT FINDINGS:

Although clinical benefits of antivascular endothelial growth factor therapy were observed in ovarian cancer treatment trials, this use yielded only modest improvement in progression-free survival and, with the exception of cediranib, no effect on overall survival. Adaptive resistance and escape from antiangiogenesis therapy is likely a multifactorial process, including induction of hypoxia, vascular modulators, and immune response. New drugs targeting the tumor vasculature or other components of the surrounding microenvironment have shown promising results.

SUMMARY:

When to start and end antiangiogenesis therapy and the choice of optimal treatment combinations remain controversial. Further evaluation of personalized novel angiogenesis-based therapy is warranted. Defining the critical interaction of these agents and pathways and the appropriate predictive markers will become an increasingly important objective for effective treatment.

• Authors: Xiaoyun Yang, Fangrong Shen, Wei Hu, Robert L Coleman, Anil K Sood
• Journal: Current opinion in obstetrics & gynecology (Curr Opin Obstet Gynecol) Vol. 27 Issue 1 Pg. 58-65 (Feb 2015) ISSN: 1473-656X [Electronic] England
• PMID: 25502429 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Disease-Free Survival
• Female
• Humans
• Neovascularization, Pathologic (drug therapy)
• Ovarian Neoplasms (blood supply, drug therapy)
• Randomized Controlled Trials as Topic
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)